Find in Library

Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children. The use of biologic therapy has improved prognosis and quality of life for these patients. Remission is more easily achieved and pediatric rheumatologists started to question if, when and how this expensive and potentially dangerous treatment might be withdrawn. To date, few studies have addressed these questions and results are divergent, more research being needed. As the latest Romanian protocol for biologic therapy in JIA includes it, and because Etanercept is the most prescribed biologic drug in our country, we propose an Etanercept treatment withdrawal protocol for JIA patients in remission.